Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2 Trial of Pidnarulex in MYC Aberrant Lymphoma

NCT07069699 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT07069699
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07069699 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2 Trial of Pidnarulex in MYC Aberrant Lymphoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 11, 2027
Completion date
January 31, 2030
Enrollment
50 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

burkitt lymphoma, double-expressor lymphoma, high grade b-cell lymphoma with myc and bcl2 and/or bcl6 rearrangements